



بسم الله الرحمن الرحيم

∞∞∞∞

تم رفع هذه الرسالة بواسطة / حسام الدين محمد مغربي

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات : لا يوجد



TGFb immunohistochemical expression in cancer associated fibroblasts in urinary bladder carcinoma

*Thesis Submitted for fulfillment of M.D
in Pathology*

By

Noha Helmy Ghanem

M.B.B.Ch, MSc of Pathology

Supervisors

Prof.Dr. Nafissa Mohammed Amin El-Badawy

Professor of Pathology

Faculty of Medicine, Ain Shams University

Prof. Dr. Sahar Saad El Din

Professor of Pathology

Faculty of Medicine, Ain Shams University.

Prof. Dr. Iman Hamed Mostafa Hewedi

Professor of Pathology

Faculty of Medicine, Ain Shams University

Prof.Dr. Lobna Sadek Shash

Professor of pathology

Faculty of Medicine, Ain Shams University

Faculty of medicine

Ain Shams University

2022

Acknowledgement

I wish to express my profound gratitude and sincere thanks to Almighty **Allah** His magnificent help is the first factor in everything we can do in our life.

I am overwhelmed in all humbleness and gratefulness to acknowledge my depth to all those who have helped me to put these ideas into something concrete.

It is a genuine pleasure to express my deep sense of thanks and gratitude to my supervisor **Prof. Dr. Nafissa El-Badawy** professor of pathology, Faculty of Medicine, Ain Shams University. Her dedication and keen interest above all her overwhelming attitude to help her students had been mainly responsible for completing my work. Her timely advice, meticulous scrutiny, scholarly advice and scientific approach have helped me to a very great extend to accomplish this task.

I would like to express my appreciation and sincere gratitude to **Prof Dr. Sahar Saad El Din** professor of pathology, Faculty of Medicine, Ain Shams University, for her continuous efforts, advice, patience and continuous constructive criticism throughout this thesis and during publication.

I would like to express my deep and sincere gratitude to my research supervisor **Prof Dr. Iman Hamed Mostafa Hewedi** professor of pathology, Faculty of Medicine, Ain Shams University. Her invaluable guidance throughout this research, dynamism, vision, sincerity and motivation had deeply inspired me.

I'd like to thank **Ass. Prof. Dr. Lobna Sadek Shash**, Assistant professor of pathology, Faculty of Medicine, Ain Shams University, for her timely suggestions with kindness, enthusiasm, dynamism, patience, technical skillful supervision and encouragement had

<i>Title index</i>	<i>pages</i>
1) List of abbreviations	I
2) List of figures	IV
3) List of tables	VI
4) List of diagrams	VII
5) Introduction	1
6) aim of the work	3
7) Review of literature	4
Embryology	4
Role of transforming growth factor-B (TGF-B) during bladder development	4
Urinary bladder carcinoma:	4
Epidemiology	4
Risk factors	5
Classifications of Urinary Bladder Urothelial Carcinoma	6
A) Pathological classification WHO classification	6
Urothelial carcinoma: Pathogenesis	8
Non invasive urothelial carcinoma	9
Invasive urothelial carcinoma	
B) Molecular classification	15
Squamous cell carcinoma	18
Risk factors	18
Grading of squamous cell carcinoma	19
Staging of urinary bladder carcinoma	19
Seed and soil crosstalk	20
The seeds: tumor stem cells feature	21
The soil: Tumor microenvironment	21
Role of TME in carcinogenesis	21
Cancer associated fibroblasts (CAFs)	22
Markers of CAFs	22
Origin of CAFs	24
Transforming Growth Factor- B	25
Structure and secretion	25
Activation	26
Mechanism of action of TGF-B	26

Significance of TGF-B in Oncogenesis	27
I) Interaction with the seed (cancer cell)	27
The SMAD pathway is one of the most important pathways involved in TGF-B1 functions	
II) Interaction with the soil (tumor microenvironment)	28
• Interaction of TGF-B1 with CAFs	28
• Interaction of TGF-B1 with tumor immune microenvironment (TIME) key players	29
III) Role of TGF-B1 in angiogenesis	29
IV) Role of TGF-B1 in epithelial-mesenchymal transdifferentiation (EMT)	30
V) Role of TGFB in cancer metastasis:	31
VI) Role of TGF-B in cancer metabolism	
Established role of TGF-B in some cancers	32
Role of TGF-B1 in Urinary Bladder Carcinoma (UBC)	32
Role of TGF-B in Serous Ovarian Cancer	32
Role of TGF-B in Prostate Cancer	32
Targeting TGF-B in cancer treatment	32
Targeting TGF-B in cancer treatment	32
TGF-B pathway inhibitors	
8) Material and methods	34
9) Results	40
10) Discussion	63
11) Summary	67
12) Conclusion	69
13) Recommendations	70
14) References	71
15) Arabic summary	1

List of Abbreviations

AJCC	<i>American Joint Committee on Cancer</i>
AMH	<i>anti-mullerian hormone</i>
APC	<i>Antigen representing cell</i>
APOBEC	<i>Apolipoprotein B mRNA editing enzyme</i>
ASK1	<i>apoptosis signal-inducing kinase 1</i>
BMPs	<i>bone morphogenic proteins</i>
CAFs	<i>Cancer associated fibroblasts</i>
CDKN2A	<i>cyclin-dependent kinase inhibitor 2A</i>
CIS	<i>Carcinoma in situ</i>
coSMAD	<i>the common SMAD</i>
CSCs	<i>cancer stem cells</i>
CTGF	<i>connective-tissue growth factor</i>
DAB	<i>Diaminobenzidine</i>
EAU	<i>European Association of Urology</i>
ECM	<i>extracellular matrix</i>
EGFR	<i>epidermal growth factor receptor gene</i>
ELF3	<i>E74-like ETS transcription factor 3</i>
EMT	<i>Epithelial-to-mesenchymal transition</i>
EndMT	<i>endothelial-mesenchymal transition</i>
ERCC2	<i>excision repair cross-complementing rodent repair deficiency, complementation group 2</i>
FAP	<i>Fibroblast activation protein</i>
F.E	<i>Fisher's exact test</i>
FGFR3	<i>fibroblast growth factor receptor 3</i>
FSP-1	<i>Fibroblast specific protein-1</i>
GCO	<i>Global Cancer Observatory</i>
GDFs	<i>growth and differentiation factors</i>

GIT	<i>Gastrointestinal tract</i>
H&E	<i>Haematoxylin and eosin</i>
HER2	<i>human epidermal growth factor receptor 2</i>
HG	<i>High grade</i>
HIER	<i>Heat-induced epitope retrieval</i>
HIF1	<i>hypoxia-inducible factor 1</i>
IHC	<i>Immunohistochemistry</i>
IFNγ	<i>Interferon gamma</i>
ISUP	<i>International Society of Urological Pathology</i>
iTregs	<i>induced Tregs</i>
IUC	<i>Invasive urothelial carcinoma</i>
JNK	<i>the Jun amino-terminal kinase</i>
KD	<i>Kilo Dalton</i>
KDM6A	<i>lysine-specific demethylase 6A</i>
LAB	<i>Labeled avidin–biotin</i>
LAP	<i>latency associated peptide</i>
LDL	<i>Low-density lipoprotein</i>
LP	<i>Lamina propria</i>
LTBP	<i>Latent TGF-β-Binding Protein</i>
LLC	<i>larger complex called Large Latent Complex</i>
MIBC	<i>muscle invasive urinary bladder carcinoma</i>
MM	<i>Muscularis mucosa</i>
MMP	<i>matrix metalloproteases</i>
MP	<i>Muscularis propria</i>
NCCN	<i>National Comprehensive Cancer Network</i>
NIP LG	<i>Noninvasive papillary Low Grade urothelial carcinoma</i>
NIP HG	<i>Noninvasive papillary high grade</i>

NMIBC	<i>Non-muscle invasive urinary bladder carcinoma</i>
NPV	<i>Negative predictive value</i>
NSCs	<i>normal stem cells</i>
OS	<i>overall survival</i>
PBS	<i>Phosphate buffer saline</i>
PCR	<i>Polymerase chain reaction.</i>
PI 3-kinase	<i>Phosphoinositide 3-kinase</i>
PMN	<i>pre-metastasis niches</i>
PPV	<i>Positive predictive value</i>
PUNLM	<i>Papillary Urothelial Neoplasm of Low Malignant Potential</i>
PTC	<i>papillary thyroid carcinoma</i>
PyMT	<i>polyoma middle T</i>
RAF	<i>Rapidly Accelerated Fibrosarcoma.</i>
RAS	<i>Rat sarcoma virus</i>
R-SMAD	<i>receptor regulated SMAD</i>
ROC	<i>Receiver operating characteristic</i>
<i>r</i>	<i>Spearman's rho</i>
Rb	<i>retinoblastoma protein</i>
RT-PCR	<i>Reverse transcription polymerase chain reaction</i>
S	<i>Significant</i>
SLC	<i>Small Latent Complex</i>
SCC	<i>Squamous cell carcinoma</i>
SD	<i>Standard deviation</i>
SMA	<i>Smooth muscle actin</i>

Smads (or SMADs)	<i>abbreviation refers to the homologies to the Caenorhabditis elegans SMA ("small" worm phenotype) and MAD family ("Mothers Against Decapentaplegic") of genes in Drosophila.</i>
SPSS	<i>Statistical Package for the Social Sciences</i>
SNPs	<i>single-nucleotide polymorphisms</i>
TGFB- TGFb TGF-B	<i>Transforming growth factor beta</i>
TGFBRI	<i>TGF-B receptor I</i>
TME	<i>Tumor microenvironment</i>
TSP-1	<i>thrombospondin-1</i>
t- test	<i>Student t test</i>
TURBT	<i>Transurethral resection</i>
UBC	<i>cancer of the urinary bladder</i>
UC	<i>Urothelial carcinoma</i>
VEGFC	<i>vascular endothelial growth factor</i>
WHO	<i>World health organization</i>
X2	<i>Chi square</i>

List of Figures

Figure No.	Title	Page No.
Figure 1:	PUNLMP	10
Figure 2:	low-grade papillary urothelial carcinoma	10
Figure 3:	high-grade papillary urothelial carcinoma	10
Figure 4:	A case of invasive urothelial carcinoma with squamoid differentiation showing strong expression of TGF-B1 in both the tumor cells as well as the CAFs (IHC x100).	49
Figure 5:	A closer view to the previous case to show strong nuclear expression of TGF-B1 in the tumor cells as well as cytoplasmic and membranous (IHC x200).	49
Figure 6:	High grade urothelium carcinoma show nuclear and cytoplasmic expression of TGF-B1 (IHC x200).	50
Figure 7:	moderate to strong cytoplasmic expression of TGF-B1 in low grade invasive papillary urothelial carcinoma (H&E 400).	50
Figure 8:	squamous cell carcinoma cells are negative to TGF-B1 but shielding themselves by CAFs which strongly express TGF-B1 (H&E 100).	51
Figure 9:	a case of invasive urothelial carcinoma with strong cytoplasmic expression of TGF-B1 with membranous accentuation (IHCx400)	51
Figure 10:	urothelial carcinoma with cystitis glandularis (H&E 100).	52
Figure 11:	urothelial carcinoma with cystitis glandular is showing strong expression to TGF-B1 (IHC 100).	52
Figure 12:	a case of papillary urothelium carcinoma the cells show cytoplasmic and membranous accentuation to TGF-B1. The basement membrane is highlighted in contrast to negative fibroblasts in the core (H&E 100).	53

Figure 13:	the expression of TGF-B1 is mainly cytoplasmic in contrast to negative fibroblasts (IHCx200)	53
Figure 14:	A case of noninvasive urothelial carcinoma showing TGF-B1 stain in cytoplasmic and membranous in contrast to negative fibroblasts in the core (IHCx100).	54
Figure 15:	A case of noninvasive urothelial carcinoma showing TGF-B1 staining the cytoplasm with membranous accentuation as well as the fibroblasts in the core (IHCx100).	54
Figure 16:	carcinoma insitu with strong expression of TGF-B1 in tumor cells (IHCx40).	55
Figure 17:	carcinoma insitu with membranous expression of TGF-B1 in tumor cells (IHCx100).	55
Figure 18:	High grade urothelial carcinoma invading thick bundle of muscularis propria A:(H&Ex200) B: (IHCx200)	56
Figure 19	A ball of the tumor cells invading the muscularis propria is showing moderate membranous expression of TGF-B1 in contrast to robust expression of the CAFs shield (IHCx 200).	56
Figure 20:	A case of urothelial carcinoma where the tumor cells as well as the CAFs show expression of TGF-B1 during invading the muscularis propria. Also, the blood vessel is shielded by CAFs strongly expressing TGF-B1 (IHCx 200).	57
Figure 21:	A case of urothelial carcinoma A: infiltrating the fat (H&Ex100) B) showing spatial distribution of TGF-B1. Here the expression was stronger in the growing boundary towards the infiltrated fat (IHCx100)	57
Figure 22:	A case of urothelial carcinoma where expression of TGF-B1 in CAFs was associated with necrosis. The tumor cells are positive as well A: H&E X100 ,B: IHC X100	58
Figure 23:	A case of urothelial carcinoma associated with bilharziasis showing positive expression of TGF-B1 in CAFs and the tumor cells as well A: H&E 200 , B: IHC 400.	58

List of Tables

Table No.	Title	pages
Table I:	<i>Variants of urothelial carcinoma: clinical, pathological, and molecular features</i>	11
Table II:	<i>Molecular subtypes of non-muscle invasive bladder cancer and their main features</i>	15
Table III:	<i>Molecular subtypes of muscle invasive bladder cancer (MIBC) and their main features</i>	16
Table IV:	<i>TNM staging of urinary bladder carcinoma</i>	19
Table (V):	<i>Markers of CAFs</i>	24
Table VI:	<i>Clinicopathological parameters</i>	40
Table VII:	<i>Correlation between the TGF-B1 expression in CAFs with all pathological parameters</i>	42
Table VIII:	<i>localization of TGF-B1 expression in cancer cells</i>	46
Table IX:	<i>Correlation between the TGF-B1 in tumor with the pathological parameters:</i>	46
Table X	<i>Correlation between the immunohistochemistry marker in tumor and fibroblasts</i>	47

List of diagrams

<i>Diagram No.</i>	<i>Title</i>	<i>page</i>
<i>Diagram 1:</i>	<i>Overview of staging of tumors arising from the urinary bladder, diverticulum, and urachal remnants</i>	20
<i>Diagram 2:</i>	<i>Tumor microenvironment showing representative cell types, tissues, and signaling factors involved</i>	23
<i>Diagram 3:</i>	<i>Origins of cancer-associated fibroblasts in the tumor microenvironment (TME) and role in cancer progression</i>	23
<i>Diagram 4:</i>	<i>latent TGF-B1 complexes</i>	26
<i>Diagram 5:</i>	<i>Summary of the effects of TGFB at the microenvironment level.</i>	31
<i>Diagram 6:</i>	<i>represent the significant difference with tumor type being highly expressed in all tumor subtypes except TCC without any specific differentiation</i>	43
<i>Diagram 7:</i>	<i>Represent high expression TGF-B1 in CAFs was significantly associated with higher stage</i>	44
<i>Diagram 8:</i>	<i>Represent high expression TGF-B1 in CAFs was significantly associated with higher grade urothelial carcinoma</i>	44
<i>Diagram 9:</i>	<i>Represent high expression of TGF-B1 in CAFs was significantly associated with presence of bilharziasis</i>	45
<i>Diagram 10:</i>	<i>Represent high expression TGF-B1 in CAFs was significantly associated with necrosis</i>	45
<i>Diagram 11:</i>	<i>Represent there was difference between expression of TGF-B1 in CAFs and tumor cell</i>	48

ABSTRACT

BACKGROUND: Urinary bladder carcinoma (UBC) is one of the most common malignancies in Egypt and all over the world. Transforming growth factor beta (TGFB) levels in plasma and urine were proved to connote predictive and prognostic attributes in UBC patients. Furthermore, Cancer-associated fibroblasts (CAFs) are, now, recognized as a key player in carcinogenesis. Yet, TGFB1 expression in CAFs of UBC had not been elucidated. Moreover, TGFB1-targeted therapy is now emerging with potential benefits for TGFB1 expressing cancers.

AIM OF THE STUDY: We dedicated this study to explore potential implications of TGFB1 immunohistochemical expression in CAFs of UBC by correlating it to relevant clinical and pathological data.

MATERIALS AND METHODS: This retrospective study included 48 UBC specimens. Different tumor grades were presented in balanced groups. TGFB1 immunohistochemical expression was evaluated, categorized as low or high and compared in CAFs among different UBC grades, statistical analysis of the results was then followed.

RESULTS: TGFB1 expression in CAFs was significantly different among tumor histologic types ($p = 0.01$), high tumor grade ($p \leq 0.01$), presence of muscle invasion ($p \leq 0.001$), higher tumor stage ($p = 0.01$), presence of preceding bilharziasis ($p = 0.003$), and necrosis ($p = 0.03$). There was a highly significant difference between TGFB1 expression in both tumor cells and CAFs ($p = 0.002$). Intense CAFs TGFB1 staining was also strikingly observed along the muscle invading frontside of UBC cells further emphasizing the pivotal role of CAFs expressing TGFB1 in invasion.

CONCLUSION: This study demonstrates significant predictive implications of TGFB1 in UBC, thus emphasizing its potential benefits in management and therapy.

Keywords: Transforming growth factor beta1; Urinary bladder cancer; Cancer-associated fibroblast; Cancer-associated fibroblasts; Immunohistochemistry.

Introduction

Urinary bladder cancer (UC) is the 10th most common form of cancer worldwide with an estimated 573,000 new cases and 213,000 deaths of all sites in both sexes in 2020 according to Global Cancer Observatory (GCO). In Egypt, according to GCO, UC is ranking the 3rd most common cancer after liver and prostatic cancers in both sexes of all ages in 2020. The number of new cases in Egypt in 2020 in both sexes and all ages is 10655/134632 representing 7.9% of all cancers **(Sung et al., 2021)**.

More than 95% of bladder tumors are of epithelial origin. The urothelial neoplasms are the most common type followed by squamous and glandular neoplasms **(Humphrey et al., 2016)**.

Cancer cells can't survive nor grow without hospitable microenvironment. This tumor microenvironment (TME) is an active participant in tumorigenesis rather than passive observer. It consists mainly of resident cells, secreted growth factors, and extracellular matrix proteins **(Bhowmick et al., 2004)**. Recognition of TME concept had revolutionized cancer treatment modalities **(Hainaut et al., 2013)**.

Fibroblasts association with cancer cells attain special phenotype and are called cancer associated fibroblasts (CAFs). CAFs are usually derived from the resident fibroblasts in the